Salmonella enterica serovar Tphi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever

Clinical and Vaccine Immunology

Volumn 14, Issue 10, 2007, Pages 1285-1295

  Fraillery, Dominique ^a   Baud, David ^a   Pang, Susana Yuk Ying ^b   Schiller, John ^b   Bobst, Martine ^a   Zosso, Nathalie ^a   Ponci, Françoise ^a   Nardelli Haefliger, Denise ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CVD908 HTRA; IMMUNOGLOBULIN G; KANAMYCIN; LIVE VACCINE; PHOP PROTEIN; SALMONELLOSIS VACCINE; TY21A KANL1S; TY800; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; ELECTRON MICROSCOPY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA ENTERICA; SEROTYPE; TYPHOID FEVER; UTERINE CERVIX CANCER; VIRUS LIKE AGENT;

ANIMALS; CANCER VACCINES; CAPSID PROTEINS; CELLS, CULTURED; FEMALE; GENETIC VECTORS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; PLASMIDS; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, ATTENUATED; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 35548933316     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00164-07     Document Type: Article

References (52)

1. Angelakopoulos, H., and E. L. Hohmann. 2000. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68:2135-2141.
2. Baker, S. J., C. Daniels, and R. Morona. 1997. Phop/q regulated genes in Salmonella typhi - identification of melittin sensitive mutants. Microb. Pathog. 22:165-179.
3. Balmelli, C., S. Demotz, H. Acha-Orbea, P. De Grandi, and D. Nardelli-Haefliger. 2002. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. J. Virol. 76:12596-12602.
4. Balmelli, C., R. Roden, A. Potts, J. Schiller, P. De Grandi, and D. Nardelli-Haefliger. 1998. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. 72:8220-8229.
5. Baud, D., F. Ponci, M. Bobst, P. De Grandi, and D. Nardelli-Haefliger. 2004. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles using a codon-optimized version of L1. J. Virol. 78:12901-12909.
6. Benyacoub, J., S. Hopkins, A. Potts, S. Kelly, J.-P. Kraehenbuhl, R. Curtiss III, P. De Grandi, and D. Nardelli-Haefliger. 1999. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus like particles determines the specific antibody responses in nasally immunized mice. Infect. Immun. 67:3674-3679.
7. Bosch, F. X., A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265.
8. Buck, C. P., D. V. Pastrana, D. R. Lowy, and J. Schiller. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757.
9. Bumann, D., C. Hueck, T. Aebischer, and T. F. Meyer. 2000. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Immunol. Med. Microbiol. 27:357-364.
10. Chen, X. S., G. Casini, S. C. Harrison, and R. L. Garcea. 2001. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16L1. J. Mol. Biol. 307:173-182.
11. Christensen, N. D., J. Dillner, C. Eklund, J. J. Carter, G. C. Wipf, C. A. Reed, N. M. Cladel, and D. A. Galloway. 1996. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184.
12. Curtiss, R. 1990. Attenuated Salmonella strains as live vectors for the expression of foreign antigens. Marcel Dekker, Inc., New York, NY.
13. Curtiss, R., J. O. Hassan, J. Herr, S. M. Kelly, M. Levine, G. G. Mahairas, D. Milich, D. Peterson, F. Schödel, J. Srinivasan, C. Tacket, S. A. Tinge, and R. Wright. 1994. Nonrecombinant and recombinant avirulent Salmonella vacines. In G. P. Talwar (ed.), Recombinant and synthetic vaccines. Narosa Publishing House, New Delhi, India.
14. Federal Register. 1994. Secondary food additives permitted in food for human consumption; food additives permitted in feed and drinking water of animals; aminoglycoside 3′-phophotransferase II, final rule. Fed. Regist. 59:26700-26711.
15. Galen, J. E., O. G. Gomezduarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. 1997. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15:700-708.
16. Gentschev, I., G. Dietrich, S. Spreng, B. Beuhaus, E. Maier, R. Benz, W. Goebel, J. Fensterle, and U. R. Rapp. 2004. Use of the α-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain. Int. J. Med. Microbiol. 294:363-371.
17. Germanier, R., and E. Fürer. 1975. Isolation and characterization of galE mutant Ty 21a of Salmonella typhi. A candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:553-558.
18. Harro, C. D., Y. Y. Pang, R. B. Roden, A. Hildesheim, Z. Wang, M. J. Reynolds, T. C. Mast, R. Robinson, B. R. Murphy, R. A. Karron, J. Dillner, J. T. Schiller, and D. R. Lowy. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292.
19. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. Phop/phoq-deleted Salmonella typhi (ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
20. Hoiseth, S. K., and B. A. D. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238-239.
21. Hone, D. M., A. M. Harris, S. N. Chatfield, G. Dougan, and M. M. Levine. 1991. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 9:810-816.
22. Hopkins, S., J.-P. Kraehenbuhel, F. Schödel, A. Potts, D. Peterson, P. De Grandi, and D. Nardelli-Haefliger. 1995. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:3279-3286.
23. Kirnbauer, R., F. Booy, N. Cheng, D. R. Lowy, and Y. T. Schiller. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. 89:12180-12184.
24. Lee, J. S., K. S. Shin, J. G. Pan, and C. J. Kim. 2000. Surface-displayed viral antigens on Salmonella carrier vaccine. Nat. Biotechnol. 18:645-648.
25. Levine, M. M., C. Ferreccio, P. Abrego, M. O. San, E. Ortiz, and S. Cryz. 1999. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17(Suppl. 2):S22-S27.
26. Levine, M. M., C. O. Tacket, and M. B. Sztein. 2001. Host-Salmonella interaction: human trials. Microbes Infect. 3:1271-1279.
27. Levine, M. M., G. C. Woodrow, J. B. Kaper, and G. S. Cobon. 1997. Attenuated Salmonella as a live vector for expression of foreign antigens. Marcel Dekker, Inc., New York, NY.
28. Londono-Arcila, P., D. Freeman, H. Kleanthous, A. M. O'Dowd, S. Lewis, A. K. Turner, E. L. Rees, T. J. Tibbitts, J. Greewood, T. P. Monath, and M. J. Darsley. 2002. Attenuated Salmonella, enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect. Immun. 70:5096-5106.
29. Lowy, D., and P. M. Howley. 2001. Papillomaviruses, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
30. Lowy, D., and J. Schiller. 2006. Prophylactic human papillomavirus vaccines. J. Clin. Investig. 116:1167-1173.
31. Metzger, W. G., E. Mansouri, M. Kronawitter, S. Diescher, M. Soerensen, R. Hurwitz, D. Bumann, T. Aebischer, B. U. von Specht, and T. F. Meyer. 2004. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 22:2273-2277.
32. Miller, S. I., A. M. Kukral, and J. J. Mekalanos. 1989. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc. Natl. Acad. Sci. USA 86:5054-5058.
33. Miller, S. I., and J. J. Mekalanos. 1990. Constitutive expression of the phoP regulon attenuates Salmonella virulence and survival within macrophages. J. Bacteriol. 172:2485-2489.
34. Nardelli-Haefliger, D., F. Lurati, D. Wirthner, F. Spertini, J. T. Schiller, D. R. Lowy, F. Ponci, and P. De Grandi. 2005. Immune responses induced by lower airway mucosal immunization with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23:3634-3641.
35. Nardelli-Haefliger, D., R. Roden, C. Balmelli, A. Potts, J. Schiller, and P. De Grandi. 1999. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J. Virol. 74:9609-9613.
36. Nardelli-Haefliger, D., R. Roden, J. Benyacoub, R. Sahli, J. P. Kraehenbuhl, J. T. Schiller, P. Lachat, A. Potts, and P. Degrandi. 1997. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. 65:3328-3336.
37. Nardelli-Haefliger, D., D. Wirthner, J. Schiller, D. R. Lowy, A. Hildesheim, F. Ponci, and P. De Grandi. 2003. Specific antibody levels at the cervix during the menstrual-cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95:1128-1137.
38. Nardelli-Haefliger, D., J. P. Kraehenbuhl, R. Curtiss III, F. Schodel, A. Potts, S. Kelly, and P. De Grandi. 1996. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect. Immun. 64:5219-5224.
39. Parkin, D. M. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030-3044.
40. Pasetti, M. F., M. M. Levine, and M. B. Sztein. 2003. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine 21:401-418.
41. Pasetti, M. F., T. E. Pickett, M. M. Levine, and M. B. Sztein. 2000. A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine 18:3208-3213.
42. Pastrana, D. V., C. B. Buck, Y. Y. Pang, C. D. Thompson, P. E. Castle, P. C. FitzGerald, S. K. Kjaer, S., D. R. Lowy, and J. T. Schiller. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
43. Pickett, T. E., M. F. Pasetti, J. E. Galen, M. B. Sztein, and M. M. Levine. 2000. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect. Immun. 68:205-213.
44. Revaz, V., R. Zurbriggen, C. Moser, Y. T. Schiller, F. Ponci, M. Babst, and D. Nardelli-Haefliger. 2007. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants Res. 76:78-85.
45. Rose, C. R., W. I. White, M. Li, J. A. Suzich, C. Lane, and R. L. Garcea. 1998. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J. Virol. 72:6151-6154.
46. 4 on the surface of Salmonella enterica using the autotransporter MisL. Infect. Immun. 70: 3611-3620.
47. Schödel, F. 1992. Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. Adv. Virus Res. 41:409-446.
48. Schödel, F., G. Enders, M.-C. Jung, and H. Will. 1990b. Recognition of a hepatitis B virus nucleocapsid T-cell epitope expressed as a fusion protein with the subunit B of Escherichia coli heat labile enterotoxin in attenuated salrnonellae. Vaccine 8:569-572.
49. Tacket, C. O., J. Galen, M. B. Sztein, G. Losonsky, T. L. Wyant, J. Nataro, S. S. Wasserman, R. Edelman, S. Chatfield, G. Dougan, and M. M. Levine. 2001. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. 97:146-153.
50. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, J. P. Nataro, R. Edelman, D. Pickard, G. Dougan, S. N. Chatfield, and M. M. Levine. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:452-456.
51. Tacket, C. O., M. B. Sztein, S. S. Wasserman, G. Losonsky, K. L. Kotloff, T. L. Wyant, J. P. Nataro, R. Edelman, J. Perry, P. Bedford, D. Brown, S. Chatfield, G. Dougan, and M. M. Levine. 2000. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68:1196-1201.
52. Wang, J. Y., M. F. Pasetti, F. Noriega, R. J. Anderson, S. S. Wasserman, J. E. Galen, M. B. Sztein, and M. M. Levine. 2001. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated ΔguaBA Salmonella enterica serovar Typhi strain CVD915. Infect. Immun. 69:4734-4741.